Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 905.46B |
| Revenue (ttm) | 222.47B |
| Net Income (ttm) | 45.37B |
| Shares Out | 1.01B |
| EPS (ttm) | 45.03 |
| PE Ratio | 20.00 |
| Forward PE | 19.29 |
| Dividend | 3.00 (0.33%) |
| Ex-Dividend Date | Jul 26, 2024 |
| Volume | 2,335,020 |
| Average Volume | 1,150,152 |
| Open | 898.50 |
| Previous Close | 899.85 |
| Day's Range | 872.00 - 898.75 |
| 52-Week Range | 855.10 - 1,324.30 |
| Beta | 0.47 |
| RSI | 45.68 |
| Earnings Date | May 16, 2025 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management... [Read more]
Financial Performance
In 2023, Zydus Lifesciences's revenue was 195.47 billion, an increase of 13.40% compared to the previous year's 172.37 billion. Earnings were 38.60 billion, an increase of 96.88%.
Financial StatementsNews
Zydus gets USFDA final approval for Ketoconazole Shampoo, 2%
Zydus Lifesciences Limited has secured final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ketoconazole Shampoo, 2% (a generic version of Nizoral® Sham...
Zydus Lifesciences shares surge over 4% after USFDA approval for generic Dasatinib tablets
Shares of Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) jumped 4.11% to ₹923.90 on March 6, 2025, after the company received final approval from the United States Food and Drug Administration (USFDA) to man...
Stocks to watch today, March 6: Zydus Lifesciences, Castrol India, TCS, Wipro, Ola Electric and more
The Indian stock market saw a significant rebound on Wednesday (March 5), as benchmark indices surged following value buying in utilities, power stocks, and a positive global market trend. The BSE Sen...
Zydus Lifesciences secures USFDA approval for Dasatinib Tablets
Zydus Lifesciences Limited has received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture Dasatinib Tablets in multiple strengths—20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and...
Zydus Lifesciences launches ANVIMO for transplant patients
Zydus Lifesciences, a global leader in innovation-driven healthcare, has introduced ANVIMO (Letermovir) in India, a groundbreaking advancement in the prevention of Cytomegalovirus (CMV) infection for ...
Zydus To Develop Combination Vaccine For Shigellosis And Typhoid
Zydus Lifesciences on Tuesday said it will undertake development of a combination vaccine against shigellosis and typhoid.
Zydus Lifesciences to develops world’s first shigellosis and typhoid combination vaccine
Zydus Lifesciences Limited, a global leader in life sciences and vaccine innovation, has announced its groundbreaking project to develop the world’s first combination vaccine against typhoid and shige...
Zydus gets USFDA nod for Ibuprofen and Famotidine tablets
Zydus Lifesciences Limited has recently informed exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ibuprofen and ...
Zydus Lifesciences shares surge nearly 3% after US FDA issues no observations for Ambernath unit
Zydus Lifesciences’ stock saw a nearly 3% jump after the company announced that the US FDA completed a surveillance inspection at its API Manufacturing site in Ambernath, Maharashtra, from February 10...
Zydus and Beihai Biotech sign strategic agreement for BEIZRAY product for the US market
Zydus Lifesciences Ltd., a global healthcare leader, has announced a strategic agreement between its wholly owned subsidiary, Zydus Lifesciences Global FZE, and Zhuhai Beihai Biotech Co., Ltd. The par...
Zydus signs exclusive agreement with Synthon for a novel 505(B)(2) oncology product for US market
Zydus Lifesciences Ltd., a leading global healthcare company, has signed an exclusive development, licensing, supply, and commercialization agreement with Synthon BV, Netherlands. This collaboration f...
Zydus Lifesciences Q3 FY25 Financial Results: Revenue grows 17% YoY to Rs 5269 crore, Profit surges 29.6% YoY
Zydus Lifesciences Limited reported a strong performance for the quarter ended December 31, 2024, with key financial metrics reflecting robust growth. The company’s consolidated revenue from operation...
Zydus Lifesciences chairman Pankaj R. Patel awarded Padma Bhushan for contributions to lifesciences
Mr. Pankaj R. Patel, Chairman of Zydus Lifesciences Limited, has been honored with the prestigious Padma Bhushan by the Government of India. The Padma Bhushan, one of India’s highest civilian awards, ...
Pharma Stocks Today: Biocon surges 4.41%, Mankind Pharma up 1.85%; Glaxo and Abbott India decline
Pharma stocks showed mixed trends in early trading as of 9:24 AM today. Biocon led the gainers, rising 4.41% to trade at ₹381.30, while Mankind Pharma climbed 1.85%, trading at ₹2,644.05. Top Gainers:...
Zydus announces agreement with CVS Caremark to add Zituvio and combination products to its template formulary
Zydus Lifesciences partners with CVS Caremark to add Zituvio tablets to formulary. Combination products to follow in 2025.
Zydus signs strategic agreement with CVS Caremark to add Zituvio , Zituvimet and ZituvimetTM to its template formulary
Zydus Lifesciences has recently informed exchanges that the company entered into a strategic agreement with CVS Caremark, a subsidiary of CVS Health. The agreement will see Zydus’ diabetes medications...
Zydus Lifesciences announces U.S. FDA priority review for CUTX-101, a potential first-in-class treatment for Menkes disease
Zydus Lifesciences, through its U.S.-based subsidiary Sentynl Therapeutics, has achieved a critical milestone with the U.S. FDA granting priority review to its New Drug Application (NDA) for CUTX-101 ...
Aurobindo Pharma (+1.58%), Mankind Pharma (+1.48%), Zydus Lifesciences (+0.91%) lead pharma stock gains
As of 10:00 AM, pharma stocks are trading mixed, with Aurobindo Pharma, Mankind Pharma, and Zydus Lifesciences emerging as top gainers. Meanwhile, Biocon (-0.72%), Ipca Labs (-0.40%), and Dr. Reddy’s ...
Healthcare Sector Stock Update: Sun Pharma up 1.05%, Cipla up 1.22%, Zydus Lifesciences up 2%
The healthcare sector displayed a varied performance in today’s trading session, with pharmaceutical giants leading gains while hospital operators experienced mixed trends. Gainers: Sun Pharmaceutical...
Zydus Lifesciences receives USFDA approval for Lidocaine and Prilocaine Cream USP
Zydus Lifesciences Limited has recently informed exchanges that the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine ...
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Zydus Lifesciences faces setback as SC denies interim relief in breast cancer drug case, sends matter back to Delhi HC
Shares of Zydus Lifesciences were under focus after the Supreme Court refused to grant interim relief to the company in a high-profile breast cancer drug patent case. The SC sent the case back to the ...
Zydus Lifesciences’s market cap gains Rs 1,363 crore as stock surges 1.43%
Shares of Zydus Lifesciences Limited saw a modest rise, closing at ₹963.30, a 1.43% increase from the previous close of ₹949.75. This increase led to a gain of around ₹1,363.45 crore in the company’s ...
Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ...
Zydus Lifesciences Ltd (BOM:532321) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Regulatory Challenges
Zydus Lifesciences stock drops 2% on Q2 results
Shares of Zydus Lifesciences fell more than 2% following the release of its Q2 financial results. The company’s total revenue saw a sharp decline of 41.39% quarter-on-quarter (QoQ) to ₹492.9 crore, th...